Canaccord Genuity initiated coverage on Quantum-Si with a new price target
$QSI
Industrial Machinery/Components
Industrials
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $3.00 | Buy | H.C. Wainwright |
| 9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
| 10/20/2021 | $13.00 | Buy | Canaccord Genuity |
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024.The presentation, titled "Next Generation Proteomics to Detect Disease-Relevant Proteoforms" will be on Wednesday, June 12th at 2:50 p.m. on the Omics Stage and will describe the application of Quantum-Si's Next-Generation Protein Sequencing ("NGPS") to identify protein variants that have a role in complex disease.
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024.Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Kummet
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Quantum-Si (NASDAQ:QSI) with a Buy and maintains $4 price target.
Provides Update on the Company's Innovation Roadmap & New Development Partnerships Highlights new Distribution Agreement with Avantor in the U.S. and Canada Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024. Quantum-Si's Management team announced Platinum™ Pro, the Company's evolution of Platinum, as well as Proteus™, the Company's new cutting-edge proteomics platform of the future, that is now under development. "We are very excited to have this opportunity to unveil the rapid innovation that we have achiev
Agreement Expands Access to Pioneering Proteomics Technology Across the U.S. and Canadian Markets Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE:AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions. The distribution agreement enables Avantor to offer Qu
Collaboration will Drive AI-Powered Advancements in Next-Generation Protein Sequencing™ and Accelerated Data Processing Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si's core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si's advanced single-molecule protein sequencing and detection tec
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as C
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter of 2024 on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:00 AM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event
Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024. Press Release Highlights Reported revenue of $622,000 in the second quarter of 2024 Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024 Announces the launch of the version 3 sequencing kit Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors Expect to l
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
3 - Quantum-Si Inc (0001816431) (Issuer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
10-Q - Quantum-Si Inc (0001816431) (Filer)